P. M. Gutierrez

发表

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Journal of medicinal chemistry.

11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors Still Improve Metabolic Phenotype in Male 11β-HSD1 Knockout Mice Suggesting Off-Target Mechanisms

M. Bohlooly-y, A. Turnbull, Anne White, 2013, Endocrinology.

Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.

L. Peletier, S. Hjorth, R. Pehrson, 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

Andrew G. Leach, A. Plowright, Robert D. M. Davies, 2012, Bioorganic & medicinal chemistry letters.

Identification and design of a novel series of MGAT2 inhibitors.

Malin Lemurell, Zhong-Qing Yuan, Öjvind Davidsson, 2013, Bioorganic & medicinal chemistry letters.

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

S. Barry, Cristina Gardelli, T. Klinowska, 2019, Tumor Biology.

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

S. Barry, B. Sidders, K. Hudson, 2018, Journal of Immunotherapy for Cancer.

Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.

Cristian Bodin, Andrew G Leach, James S. Scott, 2012, Journal of medicinal chemistry.

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott, T. Moss, C. Morrow, 2020 .

Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition

S. Barry, S. Fawell, A. Ramos-Montoya, 2021, Molecular Cancer Therapeutics.

Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.

James S. Scott, A. Turnbull, T. Sjögren, 2014, Journal of medicinal chemistry.

Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1 – the discovery of AZD2353

Andrew G. Leach, M. Waring, P. Macfaul, 2013 .

Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1

Andrew G. Leach, A. Plowright, M. Waring, 2013 .

Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors

A. Leach, Wendy L. Snelson, A. Birch, 2013 .

Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833

James S. Scott, T. Klinowska, D. Mcginnity, 2020 .

Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.

Andrew G. Leach, James S. Scott, Frederick W. Goldberg, 2012, Journal of medicinal chemistry.